Table 1.
Clinicopathological characteristics of the 74 patients with HGSC
| Mean or number | Range or percentage | |
|---|---|---|
| Age at diagnosis (years) | 53.41 ± 9.29 | 34–76 |
| Menopausal status | ||
| Pre-menopausal | 23 | 31.1% |
| Post-menopausal | 51 | 68.9% |
| Family history of cancer | ||
| Yes | 6 | 8.1% |
| No | 68 | 91.9% |
| Preoperative CA125 levels (IU/ml) | 2005.42 ± 3137.71 | 15–17,980 |
| FIGO stage | ||
| Stage I | 10 | 13.5% |
| Stage II | 6 | 8.1% |
| Stage III | 52 | 70.3% |
| Stage IV | 6 | 8.1% |
| Lymphatic metastasis | ||
| Yes | 28 | 37.8% |
| No | 46 | 62.2% |
| Cytoreductive surgery | ||
| Residual tumor ≤ 1 cm | 53 | 71.6% |
| Residual tumor > 1 cm | 22 | 29.7% |
| Current status | ||
| NED | 25 | 33.8% |
| AWD | 19 | 25.7% |
| DOD | 30 | 40.5% |
HGSC high-grade sercous carcinoma, FIGO International Federation of Gynecology and Obstetrics, NED no evidence of disease, AWD alive with disease, DOD die of disease